Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

An expert discusses how CT scans and bone scans remain the standard imaging approach for most patients with metastatic ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

The FDA granted fast track designation to TRE-515 plus radioligand therapy for treating PSMA-positive metastatic castration-resistant prostate cancer.

Bristol Myers Squibb has opened its radiopharmaceutical manufacturing facility in Indianapolis, which played a major role in ...

Take a closer look at the radiopharma new wave as Nuclidium and Actithera raise big to develop their platforms.

There are a series of other early-stage clinical candidates in the pipeline, including a PSMA-directed prostate cancer radionuclide therapy that could rival Novartis’ fast-growing Pluvicto ...

That was followed in 2019 by a $2.1 billion purchase of Endocyte and its prostate cancer RLT Pluvicto (lutetium [lu177] vipivotide tetraxetan), which made sales of almost $1 billion in 2023 and ...

A new type of medical treatment is scheduled to travel the highways and byways from headquarters in Temple in an effort to ...

Nuclidium’s radiopharmaceutical platform is unique in its use of copper-based payloads, which the biotech claims can deliver higher doses while also being safer.